91590-76-0
Chemical Structure
Momordicine I
- CAS No.: 91590-76-0
- Formula:C30H48O4
- Molecular Weight:472.70
IUPAC Name: (3S,7S,8S,9R,10R,13R,14S,17R)-3,7-dihydroxy-17-((2R,4R)-4-hydroxy-6-methylhept-5-en-2-yl)-4,4,13,14-tetramethyl-1,2,3,4,7,8,10,11,12,13,14,15,16,17-tetradecahydro-9H-cyclopenta[a]phenanthrene-9-carbaldehyde
InChIKey: QBXNBPFTVLJTMK-MKVXWLNSSA-N
SMILES: O=C[C@@]([C@@](CC[C@@H]1O)([H])C(C(C)1C)=C[C@@H]2O)(CC[C@@]34C)[C@]2([H])[C@@]3(CC[C@]4([H])[C@H](C)C[C@@H](O)/C=C(C)\C)C
Biological Activity: Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Momordicine I | 97.0% | Momordicine I is a cucurbitane-type triterpenoids. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. Momordicine I inhibits glycolysis, lipid metabolism, induces autophagy in HNC cells to suppress head and neck cancer growth. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ. Momordicine I exerts its cardiovascular benefits by upregulating nitric oxide, inhibiting the activity of angiotensin-converting enzyme (ACE), activating the PI3K/Akt pathway, reducing oxidative stress and inflammation. Momordicine I inhibits AKT1, IL-6, and SRC, suggesting its potential application in type 2 diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Li H, et al. Momordicine I alleviates isoproterenol-induced cardiomyocyte hypertrophy through suppression of PLA2G6 and DGK-ζ. Korean J Physiol Pharmacol. 2023 Jan 1;27(1):75-84. [Content Brief]
- [2]. Kao Y, et al. Momordicine I suppresses glioma growth by promoting apoptosis and impairing mitochondrial oxidative phosphorylation. EXCLI J. 2023 Jun 6;22:482-498. [Content Brief]
- [3]. Bandyopadhyay D, et al. Momordicine-I suppresses head and neck cancer growth by modulating key metabolic pathways. Cell Commun Signal. 2024 Dec 18;22(1):597. [Content Brief]
- [4]. Kao PF, et al. Therapeutic Potential of Momordicine I from Momordica charantia: Cardiovascular Benefits and Mechanisms. Int J Mol Sci. 2024 Sep 29;25(19):10518. [Content Brief]
- [5]. Niu Y, et al. Comprehensive Studies on the Regulation of Type 2 Diabetes by Cucurbitane-Type Triterpenoids in Momordica charantia L.: Insights from Network Pharmacology and Molecular Docking and Dynamics. Pharmaceuticals (Basel). 2025 Mar 27;18(4):474. [Content Brief]
Keywords
